Alexandr Nikolaevich Kholstov

Dr. Alexandr Nikolaevich Kholstov


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AGArtem Evgenievich Gusev
Artem Evgenievich Gusev
VIVladimir Nikolaevich Ivanov
Vladimir Nikolaevich Ivanov
NDNikolai Andreevich Dmitriev
Nikolai Andreevich Dmitriev
AKAlexandr Nikolaevich Kholstov
Alexandr Nikolaevich Kholstov
VVVladislav Aleksandrovich Vasilichin
Vladislav Aleksandrovich Vasilichin
MKMusa Rakhimovich Khaitov
Musa Rakhimovich Khaitov
N-Acetylgalactosamine (GalNAc) is an efficient and multifunctional delivery tool in the development and synthesis of chemically modified oligonucleotide therapeutics (conjugates). Such therapeutics demonstrate improved potency in vivo due to the selective and efficient delivery to hepatocytes in the liver via receptor-mediated endocytosis, which is what drives the high interest in this molecule. The ways to synthesize such structures are relatively new and have not been optimized in terms of the yields and stages both in lab and large-scale synthesis. Another significant criterion, especially in large-scale synthesis, is to match ecological norms and perform the synthesis in accordance with the Green Chemistry approach, i.e., to control and minimize the amounts of reagents and resources consumed and the waste generated. Here, we provide a robust and resource effective pot-economy method for the synthesis of triantennary GalNAc and GalNAc phosphoramidite/CPG optimized for laboratory scales.

1 January 2025 in Immunologiya
Verified
Journal Article
Open access
PCPetr Vladimirovich Chernov
Petr Vladimirovich Chernov
NDNikolai Andreevich Dmitriev
Nikolai Andreevich Dmitriev
AGArtem Evgenievich Gusev
Artem Evgenievich Gusev
AKAlexandr Nikolaevich Kholstov
Alexandr Nikolaevich Kholstov
MKM.V. Khodzhava
M.V. Khodzhava
IKIlya Kofiadi
Ilya Kofiadi
Разработка и валидация алгоритмов поиска, оценки и модификации миРНК, применимых для терапии патологий иммунной системы, на примере гена APOB

Verified
Journal Article
Open access
PDF file
PCPetr Vladimirovich Chernov
Petr Vladimirovich Chernov
VIVladimir Nikolaevich Ivanov
Vladimir Nikolaevich Ivanov
NDNikolai Andreevich Dmitriev
Nikolai Andreevich Dmitriev
AGArtem Evgenievich Gusev
Artem Evgenievich Gusev
VKValeriia I. Kovchina
Valeriia I. Kovchina
MKMusa R. Khaitov
Musa R. Khaitov
Every year, the scientific community continues to drive advances in healthcare, opening up new perspectives in the treatment and management of various diseases. Despite vast strides being made in the quality of life and longevity, we still face an equally significant growth in the burden of oncological pathologies. Although current trends lean towards preventive and personalized medicine, numerous hurdles remain to be cleared to develop robust strategies in the field of oncology. Among all types of tumors, one of the prominent positions is occupied by hepatocellular carcinoma (HCC), which is one of the most widespread primary cancers with a high mortality rate. Conventional approaches to HCC therapy, such as surgery or chemotherapy, rarely provide steady performance due to the highly polymorphous nature of the cancerous process. In this study, we suggest an alternative methodological framework for designing potent siRNAs targeting genes implicated in hepatocellular carcinoma, implementing RNA interference mediated by synthetic small interfering RNAs (siRNAs) against mRNAs of ITGB1 and CD47 genes. Products of these genes are renowned drivers of tumor progression. We have developed a software algorithm for the design of unmodified and modified siRNAs, carried out solid-phase synthesis of the most promising molecules, and proved their capability to perform a more than 50-fold suppression of expression of the target genes in vitro.